Welcome to our dedicated page for Kenvue SEC filings (Ticker: KVUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Kenvue Inc. (NYSE: KVUE) SEC filings, giving investors a primary source for the company’s regulatory disclosures. As the world’s largest pure-play consumer health company by revenue, Kenvue uses its SEC reports to detail financial performance, risk factors, governance matters and significant corporate events related to its portfolio of brands such as Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena®, Tylenol® and Zyrtec®.
Among the most important documents for KVUE are current reports on Form 8-K. In 2025, Kenvue filed several 8-Ks to furnish quarterly earnings press releases and to describe leadership changes, preliminary financial results and the Board’s comprehensive review of strategic alternatives. A key 8-K filed on November 3, 2025 outlines an Agreement and Plan of Merger with Kimberly-Clark Corporation, under which a Kimberly-Clark subsidiary will merge with and into Kenvue and Kenvue will ultimately become part of a wholly owned Kimberly-Clark subsidiary. That filing explains the merger structure, the cash and stock consideration for each share of Kenvue common stock, conditions to closing, and termination and fee provisions.
Investors can also use Kenvue’s filings to understand how management presents non-GAAP financial measures. The company’s 8-K earnings materials define metrics such as Adjusted gross profit margin, Adjusted operating income and margin, Adjusted net income, Adjusted diluted earnings per share, Adjusted EBITDA margin, Adjusted effective tax rate, Free cash flow and Organic sales, and reconcile them to the most comparable U.S. GAAP measures. These disclosures clarify how Kenvue evaluates operating efficiency, profitability and cash generation over time.
On this page, Stock Titan surfaces Kenvue’s SEC submissions as they are made available on EDGAR and pairs them with AI-powered summaries to explain the key points in plain language. Users can quickly scan new 10-K and 10-Q reports when filed, review 8-Ks for material events such as the Kimberly-Clark merger agreement or leadership transitions, and examine any proxy materials related to shareholder votes. This combination of real-time filings access and AI explanations helps investors follow how regulatory disclosures may affect KVUE shareholders and the future of the Kenvue business within the consumer health sector.
Kenvue Inc. insider Heather Howlett, Vice President & Chief Accounting Officer, reported two transactions in the company's common stock on
Kenvue (KVUE)189,274 restricted stock units on 10/01/2025. Each unit corresponds 1-for-1 to Kenvue common stock and carries an exercise price of $0.
The award vests in three equal installments on 10/01/2026, 10/01/2027, and 10/01/2028, contingent on continued service through each vesting date. Following the grant, 189,274 derivative securities were beneficially owned, reported as Direct (D).
Jeffrey C. Smith, a director of Kenvue Inc. (KVUE), reported transactions dated 10/01/2025. The filing shows 20,929,938 shares of Kenvue common stock are reported as indirectly beneficially owned through Starboard Value LP, which manages the Starboard Accounts holding those securities. On the same date the reporting person acquired 1,204 Deferred Share Units (DSUs), each representing the right to receive one share of common stock; these DSUs will be settled in shares following the reporting person’s separation from service and include dividend equivalents. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Smith.
Sarah Hofstetter, a Kenvue director, received 1,204 Deferred Share Units (DSUs) on 10/01/2025 under the company's Amended and Restated Deferred Fee Plan for Directors. Each DSU represents the right to one share of Kenvue common stock and will be settled in shares when the reporting person separates from service. The filing shows these DSUs include dividend equivalents and reports total beneficial ownership of 12,045.728 shares following the transaction.
This Form 4 was filed by one reporting person and signed by an attorney-in-fact. The DSUs were recorded as acquisitions and held in direct ownership form.
Kenvue Inc. (KVUE) director Richard E. Allison Jr. reported acquisition of 1,204 Deferred Share Units (DSUs) on 10/01/2025 under the company's Amended and Restated Deferred Fee Plan for Directors. Each DSU represents the right to receive one share of common stock and will be settled in shares following the reporting person's separation from service. The report shows 34,045.048 shares beneficially owned following the transaction, which includes DSUs acquired as dividend equivalents. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 10/01/2025.
Kenvue Inc. insider report: Perry Kirk, listed as Chief Executive Officer and a reporting person, acquired 185 Deferred Share Units (DSUs) on 10/01/2025 as compensation for board service. Each DSU converts to one share of Kenvue common stock and will be settled in shares following the reporting person's separation from service. After this grant (which includes dividend-equivalent DSUs), the report shows beneficial ownership of 14,041.285 shares. The filing notes the DSUs reflect pro-rated director fees for days served as an independent director in the third fiscal quarter. The form is signed by an attorney-in-fact on behalf of the reporting person.
Kenvue Inc. insider Anindya Dasgupta, Group President APAC, received equity awards on 07/31/2025. The Form 4 reports 14,925 restricted stock units (RSUs) and 124,352 stock options granted the same day. The RSUs convert 1-for-1 into common stock and both awards are held directly. The equity awards vest in three equal annual installments on 07/31/2026, 07/31/2027 and 07/31/2028, subject to continued service. The stock options have an exercise price of $21.44. Following the grants, the reporting person beneficially owns 14,925 shares from RSUs and 124,352 underlying shares from options.
Kenvue Inc. Form 3 discloses that Anindya Dasgupta, Group President APAC and an officer of the company, filed an initial ownership statement dated 07/14/2025. The filing states no securities are beneficially owned by the reporting person. The submission includes a Power of Attorney reference and is signed by an attorney-in-fact on 08/27/2025.
Kenvue Inc. (KVUE) Form 3 discloses an initial beneficial ownership filing for Michael Wondrasch, listed as Chief Tech & Data Officer and an officer/director. The report identifies the triggering event date as 08/25/2025 and states that no securities are beneficially owned by the reporting person. The filing was signed by an attorney-in-fact, Alla Berenshteyn, on 08/27/2025. The form references an attached Power of Attorney (Exhibit 24).
T. Rowe Price Associates, Inc. reports beneficial ownership of 168,318,661 shares of Kenvue Inc. common stock, equal to 8.8% of the class, in a Schedule 13G filing (Amendment No. 4). The filing shows sole voting power over 158,120,414 shares and sole dispositive power over 168,041,407 shares, and explicitly states the holdings are held in the ordinary course of business and not for the purpose of changing control.
The document identifies the issuer (CUSIP 49177J102), provides the issuer address for Kenvue, lists T. Rowe Price Associates, Inc. as the reporting person (Maryland), and is signed by Ellen York, Vice President, dated 08/14/2025 with the reportable event date of 06/30/2025.
FAQ
What is the current stock price of Kenvue (KVUE)?
What is the market cap of Kenvue (KVUE)?
